The Effectiveness of Smartphone-Based Speech Therapy for People with Post-Stroke Dysarthria (NCT05877950) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Effectiveness of Smartphone-Based Speech Therapy for People with Post-Stroke Dysarthria
100 participantsStarted 2024-09
Plain-language summary
This clinical trial aims to determine if a new smartphone-based speech therapy is effective self-treatment method for patients with post-stroke dysarthria. For this study, participants in the intervention group will use the speech therapy app for 1 hour per day, 5 days per week, over a 4-week period. The active control group will receive home-based speech therapy with the same duration and frequency as the intervention group.
The study will help us understand if smartphone-based speech therapy is a viable treatment option for post-stroke dysarthria patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18 or over.
✓. Neurologically stable stroke patients diagnosed by a stroke specialist neurologist.
✓. Diagnosis of dysarthria caused by stroke as confirmed by a stroke specialty neurologist.
✓. First-ever stroke patients without previous stroke history.
✓. Patients with sufficient cognitive abilities to operate the smartphone-based speech therapy application (Mini-Mental State Exam score ≥ 26)
✓. As judged by the neurology specialists: patients with sufficient vision, hearing, communication skills, and motor skills to participate in this study
✓. Must have voluntarily understood the trial and signed a consent form agreeing to comply with precautions.
Exclusion criteria
✕. Co-existing language disorder (e.g., aphasia). Aphasia will be determined by a stroke specialist.
✕. Co-existing progressive neurological disorders that can affect dysarthria (e.g., dementia, Pick's disease, Huntington's disease, Parkinson's disease, or Parkinsonism).
✕. Diagnosis of severe mental disorders as determined by a clinician (e.g., depression, schizophrenia, alcohol addiction, or drug addiction).
✕. Patients taking concomitant medications that could affect the trial results during the study period (e.g., cognitive dysfunction medications, anticholinergics, anti-epileptic drugs, anti-anxiety drugs, antidepressants, antipsychotics, and hypnotics).